Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Protocol | EA3132 |
---|---|
Cancer Type: | Head and Neck |
Fast Facts |
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1701 |
---|---|
Cancer Type: | Thymic Carcinoma |
A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG HN001 |
---|---|
Cancer Type: | Nasopharyngeal Carcinoma |
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Protocol | NRG HN007 |
---|---|
Cancer Type: | NASOPHARYNGEAL CARCINOMA |
AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA3161 |
---|---|
Cancer Type: | HPV Positive OPCA |
Fast Facts |
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Protocol | EA3163 |
---|---|
Cancer Type: | Nasal and Paranasal Sinus Squamous Cell Carcinoma |
Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Protocol | NRG HN004 |
---|---|
Cancer Type: | Locoregionally Advanced Head and Neck Cancer |
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
Protocol | NRG HN005 |
---|---|
Cancer Type: | Oropharyngeal Cancer |
Fast Facts |
A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Protocol | RTOG 1216 |
---|---|
Cancer Type: | Pathologic High-Risk Squamous Cell Cancer |
Fast Facts |
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | ACCRU 2018-01 |
---|---|
Cancer Type: | Untreated Solid Tumors |
Fast Facts |
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | WF 97115 |
---|---|
Cancer Type: | Head and Neck |
Fast Facts |
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.